SQI Diagnostics

183 articles about SQI Diagnostics

• SQI Diagnostics Inc Congratulates its Partner UHN for Winning $24 Million Award from Government of Canada

  1/13/2022

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD) (OTCQB: SQIDF), a precision medicine and diagnostics company focused on respiratory health, congratulates the University Health Network (UHN) for winning one of only seven prestigious "New Frontiers in Research Fund – Transformation" awards.

• SQI Diagnostics Inc. Responds to Change in FDA Priorities in Emergency Use Authorization

  10/19/2021

  SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, responded to a recent shift in US Food and Drug Administration priorities around Emergency Use Authorization.

• SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options

  9/13/2021

  SQI Diagnostics, Inc. today announced that the Company's board of directors has appointed Andrew Morris as Chief Executive Officer of the Company effective September 11, 2021.

• SQI Diagnostics Inc. Announces Grant of Stock Options - Aug 30, 2021

  8/30/2021

  SQI Diagnostics Inc., a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, announced that effective August 27, 2021, it has granted an aggregate of 3,385,000 stock options to a consultant and certain employees and officers of the Company under the Company's amended and restated stock option plan.

• SQI Diagnostics Reports Third Quarter 2021 Results

  8/18/2021

  SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the third quarter of fiscal year 2021, ended June 30th, 2021. 

• FDA Stops Emergency Use Authorization Review of SQI Diagnostics RALI-Dx IL-6 Severity Triage Test for COVID-19 Patients

  7/23/2021

  SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, announces that FDA will not continue its review of SQI's submission of the RALI-Dx™ IL-6 Severity Triage Test for Emergency Use Authorization under the "Tests for Management of COVID-19 Patients" category.

• SQI Diagnostics and AZOVA sign distribution agreement to sell SQI's COVID-19 HOME Antibody Test

  7/15/2021

  SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF),  today announced the signing of an agreement that subject to an approval by the Food & Drug Administration (FDA), will allow AZOVA to sell and distribute SQI's COVID-19 HOME Antibody Test .

• SQI Diagnostics Inc. Announces $3.9 Million Funding via Warrant Exercise by Insiders

  6/15/2021

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics today announces that certain insiders of the Company, who are control persons (the "Control Persons"),

• SQI Diagnostics Inc. Announces Grant of Stock Options

  5/27/2021

  SQI Diagnostics Inc. ("SQI" or the "Company") (TSXV: SQD) (OTCQB: SQIDF), a life sciences and diagnostics company that develops and commercializes proprietary technologies and products for advanced microarray diagnostics, today announced that effective May 27, 2021, it has granted an aggregate of 2,409,717 stock options

• SQI Diagnostics and McMaster University Announce $900,000 Collaborative Research and Development Grant

  4/13/2021

  SQI Diagnostics Inc. today announced that SQI and researchers from McMaster University were awarded a three-year, $900,000 Collaborative Research and Development grant from the Natural Sciences and Engineering Research Council of Canada to develop new infection-testing technology to help detect critical, elusive markers of illness.

• SQI Diagnostics Submits RALI-Dx; IL-6 Severity Triage Test for COVID-19 Patients to FDA for Emergency Use Authorization

  4/1/2021

  SQI Diagnostics Inc. announces that it has submitted its fully completed clinical and analytical data package to the U.S. Food and Drug Administration (FDA) for emergency use authorization

• SQI Diagnostics Receives $2.3 Million in Funds from Shareholder Exercise of Securities

  3/8/2021

  SQI Diagnostics Inc. (the "Company" or "SQI") (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide,

• SQI Diagnostics Reports First Quarter 2021 Results

  3/1/2021

  SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the first quarter of fiscal year 2021, ended December 31, 2020

• SQI Diagnostics Announces New Corporate Website

  2/18/2021

  SQI Diagnostics Inc., a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, is proud to announce the launch of its newly redesigned website at https://www.sqidiagnostics.com.

• SQI Diagnostics Reports Fourth Quarter and Fiscal 2020 Results

  1/27/2021

  SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today reported its financial and operational results for the fourth quarter and fiscal year ended September 30, 2020.

• SQI Diagnostics Announces Patient Enrollment Begins for Its COVID-19 HOME Antibody Test Clinical Study

  1/25/2021

  SQI Diagnostics Inc.(the "Company" or "SQI") ( (TSXV: SQD); (OTCQB: SQIDF), a precision medicine company that discovers, develops, and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that patient enrollment began for the Company's clinical study for its direct-to-consumer COVID-19 HOME Antibody Test

• SQI Diagnostics Announces $4 Million Funding via Warrant Exercise by Insiders

  12/30/2020

  SQI Diagnostics Inc. (TSXV: SQD) (OTCQB: SQIDF), a precision medicine company that discovers, develops and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that 19,074,997 common share purchase warrants of the Company

• SQI Diagnostics Updates Clinical Progress on Novel COVID-19 Tests Under Development for U.S. FDA Regulatory Submission

  10/26/2020

  Company Confirms COVID-19 Antibody Home Test and Two Severity Triage Tests can be Submitted to U.S. FDA Under Emergency Use Authorization

• SQI Diagnostics and McMaster University Researchers Create New Technology to Better Measure Severity of COVID-19 Disease

  10/20/2020

  SQI Diagnostics, Inc. (TSX-V: SQD) (OTCQX-US: SQIDF), a precision medicine company that discovers, develops, manufactures and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced that it, in collaboration with McMaster University researchers

• SQI Diagnostics Expanding Business into Rapid Diagnostic Testing MarketNovel Diagnostics Target Organ Transplant, Autoimmune Disease and Serological Testing, Including Two Rapid Tests for COVID-19

  9/9/2020

  SQI Diagnostics, Inc. (TSX-V: SQD; OTCQX-US: SQIDF), a precision medicine company that discovers, develops, manufactures and commercializes innovative rapid diagnostic testing for healthcare professionals, patients and consumers worldwide, today announced it is expanding its proprietary rapid diagnostic testing portfolio targeting organ transplant, autoimmune disease and serological testing.